Preventing and Treating AMR Resistant Topical Infections Utilizing Novel Sustained Release Phage Spray and Patch Systems

Lead Product – Prevention of Topical AMR Infections:

Sustained release topical designed to prevent AMR infections, with a first indication of significantly reducing pressure ulcer infections (later, labelling for this product will be expanded to include wound care, burn care, and possibly a role in diabetic ulcer care). 25% of all patients in bed for more than 7 days gets a bed sore. According to TMR analysis, in 2017, the sales volume of pressure ulcer treatment market alone was about US $4.54 billion. Due to the combined impact of aging population and antibiotic resistance, it is expected to grow to US $7.13 billion by 2026. The problem of pressure ulcer infection is very serious.

Lysigen Lead Products - Treatments for Eczema and Acne:

Important Second Product – Eczema Treatment: 

Eczema is a chronic, recurrent and inflammatory skin disease related to allergic reactions. Traditionally thought of as an autoimmune disease, however skin colonization with Staphylococcus aureus plays an important role. In different studies 54-100% of AD patients were colonized. Prevalence of S. aureus increases during AD flares. Our lead product – best-in-class ClyO staph lysin is for the topical treatment of eczema.

Important Third Product – Acne Treatment: 

Acne is an inflammatory disease of hair follicles in the skin. Main causes are increased sebum production, follicular keratinization, colonization and proliferation of Cutibacterium acnes, and inflammatory reaction and immunity. Recurring flare-ups are triggered by stress, hormonal fluctuation, pollution and allergens. Our product – first-in-class C.acnes Lysin + ClyO is for the treatment of acne.